Kazakhstan has introduced a unique technology for detecting
prostate cancer in men. At its core is a next-generation radiopharmaceutical
developed at the Nuclear Medicine Center of the Medical Center Hospital of the
President’s Affairs Administration. This drug makes it possible to detect
cancer at the earliest stages - even when it remains undetectable by
ultrasound, MRI, or CT scans. Experts say the technology represents a major
breakthrough in the field of nuclear medicine in the country.
«It took us about half a year to introduce this
radiopharmaceutical. In global practice, this process typically takes between
six months and two years. We comply with all the requirements. Complete
oversight — from the initial materials to the final production - is maintained
within our center. We can guarantee the quality of this medication,» said Baurzhan
Abyshev, Head of the Cyclotron-Production Complex at the Medical Center
Hospital of the President’s Affairs Administration of the Republic of
Kazakhstan.
«The detection rate has increased the identification of this
type of cancer by two to three times. Currently, more than 8,000 men are
affected by this cancer, with 500 to 800 new cases reported each year,» said
Aigul Saduakassova, Head of the Nuclear Medicine Center at the Medical Center
Hospital of the President’s Affairs Administration of the Republic of
Kazakhstan.
The drug offers high contrast and a long half-life, allowing
for broader use and enabling more patients to be examined each day. During the
trial phase, the first five patients have already undergone diagnostic
procedures. Overall, the Nuclear Medicine Center produces ten
radiopharmaceuticals - all aimed at the accurate diagnosis of oncological
diseases.
Related Articles
